A Multi-Center Clinical Trial To Evaluate The Efficacy And Safety Of Biib059 In Adult Participants With Active Systemic Lupus Erythematosus
Posted Date: Jul 29, 2021
- Investigator: Michael Luggen
- Type of Study: Drug
Patients with active SLE who has not responded to standard treatment will be randomized 2:1 to receive one of two doses of study medication (2/3) or placebo (1/3). The study treatment is a monoclonal antibody against plasmacytoid dendritic cells, one of the major sources of interferon in patients with lupus. Patients will remain on all standard medications for lupus and will have study medicine or placebo added. The trial will last 52 weeks. After which all patients will have the opportunity to received study drug for a period of 1 or more additional years. Treatment is given as a subcutaneous injection every month. Visits are approximately monthly as well. Compensation for time and travel is provided.
Patients With Lupus Which Remains Active Despite Current Treatment
Systemic Lupus Erythematosus
For More Information: